- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
Intervention: Pharmacological intervention
This refers to the drug, therapy, or factor being studied in a clinical trial or observational study. Examples include antiviral agents monoclonal antibodies, corticosteroids, vaccines and other pharmacological agents
- Infants (<1 year)
- Fragile population
- Hospital
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Palivizumab
- General population
- Infants (<1 year)
- Hospital
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Community
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- Respiratory syncytial virus
- Pharmacological intervention
- Vaccination
- Arexvy
- Infants (<1 year)
- Fragile population
- Hospital
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Palivizumab
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- Respiratory syncytial virus
- Pharmacological intervention
- Vaccination
- Adults (18-64 years)
- Pregnant women
- Hospital
- Outpatient clinic
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Vaccination
- Nirsevimab
- Abrysvo
- General population
- Infants (<1 year)
- Children (1-11 years)
- Primary care
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Primary care
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab